HomeCompareMGCLF vs PLD

MGCLF vs PLD: Dividend Comparison 2026

MGCLF yields 747.66% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MGCLF wins by $1570989.71M in total portfolio value
10 years
MGCLF
MGCLF
● Live price
747.66%
Share price
$0.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1570996.21M
Annual income
$1,243,755,946,498.34
Full MGCLF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — MGCLF vs PLD

📍 MGCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGCLFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGCLF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGCLF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGCLF
Annual income on $10K today (after 15% tax)
$63,551.40/yr
After 10yr DRIP, annual income (after tax)
$1,057,192,554,523.59/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, MGCLF beats the other by $1,057,188,086,552.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGCLF + PLD for your $10,000?

MGCLF: 50%PLD: 50%
100% PLD50/50100% MGCLF
Portfolio after 10yr
$785501.36M
Annual income
$621,880,601,467.26/yr
Blended yield
79.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MGCLF
No analyst data
Altman Z
-16.1
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGCLF buys
0
PLD buys
0
No recent congressional trades found for MGCLF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGCLFPLD
Forward yield747.66%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$1570996.21M$6.50M
Annual income after 10y$1,243,755,946,498.34$5,256,436.18
Total dividends collected$1544814.76M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MGCLF vs PLD ($10,000, DRIP)

YearMGCLF PortfolioMGCLF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$85,466$74,766.36$11,255$555.24+$74.2KMGCLF
2$688,646$597,197.00$13,062$1,018.59+$675.6KMGCLF
3$5,233,973$4,497,122.12$15,903$1,926.67+$5.22MMGCLF
4$37,544,137$31,943,785.57$20,839$3,823.32+$37.52MMGCLF
5$254,319,833$214,147,606.64$30,464$8,166.08+$254.29MMGCLF
6$1,627,834,568$1,355,712,346.12$52,054$19,457.30+$1627.78MMGCLF
7$9,851,651,442$8,109,868,455.03$109,886$54,188.93+$9851.54MMGCLF
8$56,411,273,720$45,870,006,676.23$304,030$186,451.18+$56410.97MMGCLF
9$305,832,024,786$245,471,961,906.33$1,166,125$840,813.32+$305830.86MMGCLF
10$1,570,996,213,020$1,243,755,946,498.34$6,504,190$5,256,436.18+$1570989.71MMGCLF

MGCLF vs PLD: Complete Analysis 2026

MGCLFStock

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

Full MGCLF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MGCLF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGCLF vs SCHDMGCLF vs JEPIMGCLF vs OMGCLF vs KOMGCLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.